Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Low-dose ASA · 1 trial · 2 indications
A binary variable indicating whether the participant had zero VTE events within 26 weeks of initiation of standard chemotherapy. VTE events include objectively confirmed symptomatic or asymptomatic proximal deep-vein thrombosis in a lower limb, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, symptomatic or incidental pulmonary embolism, symptomatic or incidental central catheter related thrombosis, or death from venous thromboembolism.
| Arm | Type | Description |
|---|---|---|
| Low-dose aspirin (acetylsalicylic acid [ASA]) | EXPERIMENTAL | ASA has been shown to reduce risk of VTE. It will be self-administered, a fixed dose of ASA (81 mg) by mouth daily for 26 weeks. |
| Name | Type | Description |
|---|---|---|
| Low-dose ASA | DRUG | 81 mg by mouth daily for 26 weeks |
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information 2. Age ≥ 18 years and ≤ 70 years at the time of consent 3. Histological confirmation of stage IS or IIA or higher testicular or germ cell cancer. Primary mediastinal and retroperitonea...
Top 20 of 45 competitors
Low-dose ASA is being studied for use in patients with advanced germ cell tumors, including testicular cancer, who are receiving chemotherapy. The investigational treatment is intended to prevent venous thromboembolism in this patient population. It is currently in Phase 2 clinical development.
Low-dose ASA is a small molecule that targets the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, to inhibit platelet aggregation. This mechanism is being evaluated for its potential to prevent blood clots in patients with advanced germ cell tumors undergoing chemotherapy.
Low-dose ASA is being developed by Atrium Therapeutics, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced germ cell tumors.
Low-dose ASA is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is recruiting participants to assess its effectiveness in preventing venous thromboembolism.
Low-dose ASA is being evaluated in a single-arm, Phase 2 clinical trial with the identifier NCT06866964. This trial is recruiting 35 patients with advanced germ cell tumors or testicular cancer who are receiving chemotherapy, and it is being conducted in the United States.
Low-dose ASA is the same as low-dose aspirin, as ASA stands for acetylsalicylic acid, the active ingredient in aspirin. In this context, it is being investigated at a low dose for its potential to prevent venous thromboembolism in patients with advanced germ cell tumors.